BenzingaDoubao · 实盘不做把握 4/10不做原因:已被定价
北京时间·🕒 发布 20:47:54·⟳ 抓取 20:50:14 +2m20s·⚡ 决策 10-15 20:55:35 +5m21s·12.1 天前
Vanda制药VQW-765治疗急性社交焦虑三期临床主要及次要终点双未达，盘前创52周新低
三期失败本身是确凿直接利空，但资产非核心收入来源、商业化产品组合与全年指引未受损；官方通稿在信号到达前约16小时（10月14日盘后）已发布，盘后交易完成主要重定价（低点-19%后收回至约-5%），开盘追空剩余edge不足且小盘低价股逼空/反弹风险高。
📄 原文Benzinga↗ 原文
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday shared an update regarding its clinical development pipeline. The…
不做 Vanda Pharmaceuticals（VNDA.US）
看空方向成立但不开空：VQW-765为无收入的非核心在研管线，商业化组合（Fanapt Q2 +23%）与全年指引未受损；官方通稿10月14日盘后已发布，盘后-19%后收回、盘前仅约-5%，价格发现隔夜基本完成，52周新低、约2.55亿美元市值的微盘股开盘追空风险收益比差且易轧空。已在risk_signals保留该直接利空供存量多头规避。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Vanda在研社交焦虑药VQW-765三期主、次要终点双未达，二期结果未复现，属确认性管线利空；但该药无当期收入，公司Fanapt等商业化产品仍在增长，且利空10月14日盘后已落地、隔夜盘后已完成从-19%到-5%的价格发现，开盘再做空edge不足，回避。
消息传播链
- Vanda官方发布VQW-765临床开发项目更新，确认Study 3201未达主要及次要终点；盘后交易股价一度下探3.43美元（约-19%）后回收市场反应:10月14日盘后低见3.4344美元、收于约4.03美元，盘后成交约23.5万股
- Benzinga盘前跟进详述试验设计与双终点未达，报道时股价约4.11美元；工具实时盘前价约4.00美元（-5.2%），创52周新低市场反应:周三盘前约4.00美元，较周二收盘4.22美元跌约5%
关键理由
- 三期主要终点（女性SUDS）与全人群次要终点均未达且二期数据未能复现，VQW-765的管线期权价值基本清零
- 股价处52周新低、20日累计下跌15.6%，情绪与趋势偏弱
主要风险
- VQW-765仅为在研管线，公司四大商业化产品（Fanapt Q2销售+23%至3600万美元）支撑收入与全年指引，利空对基本面实质损害有限
- 官方通稿10月14日盘后已发布，盘后低点3.43美元后被大幅买回到约4.0美元，显示空头预期已被消化，4美元附近的微盘低价股存在轧空反弹风险
反向证据
- 做空前查反向 · 来源 web · 日期 2026-10-15 · 影响 weakens
Vanda年报自述业绩依赖Hetlioz/Fanapt/Ponvory等商业化产品，VQW-765仅为早期在研管线之一，做空的基本面杀伤量级有限
检索:Vanda VQW-765 pipeline importance analyst peak sales social anxiety 2026 原文 ↗ - 做空前查反向 · 来源 filing · 日期 2026-08-05 · 影响 weakens
商业化组合增长强劲并有全年指引，公司未因本次失败撤回指引，不构成财务/经营层面的强空催化
检索:Vanda Q2 2026 revenue guidance Fanapt Bysanti commercial portfolio 原文 ↗ - 做空前查反向 · 来源 kb_search · 影响 none
内部KB检索服务连接被拒（Connection refused），未取得管线估值的独立交叉证据；不影响以公开通稿和财报做出的回避结论
检索:kb_search Vanda VQW-765 pipeline significance
先例如何影响了这次决策
对本次决策的影响:先例未改变回避结论；Web检索到的中外创新药三期失败案例（艾力斯、贝达/EyePoint、Immunovant等）多为核心/合作管线，量级不可比，故不纳入
方向:未构建合格对齐先例面板：本次为研究后AVOID，核心依据是事件已隔夜消化与资产非核心，历史涨幅不影响结论
涨幅量级:无可用高相似对齐样本，不用外部先例校准幅度
形态:本案自身盘后-19%后回收至-5%的隔夜走势已显示见光后抛压被承接
工具执行结果 · 成功 5 · 降级 0 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`vanda pharmaceuticals vqw-765 phase 3 missed primary endpoint social anxiety | vanda 三期临床 vqw-765 社交焦虑 主要终点未达 | vnda study 3201 alpha-7 nicotinic agonist trial failure`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有 - stock_quote 成功 stock_tools HTTP · 1,845 ms
{ - kb_search 失败 stock_tools HTTP · 57 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 doubao_search · 1,908 ms
豆包搜索结果（原始查询:Vanda Pharmaceuticals VQW-765 Phase 3 Study 3201 failed primary endpoint press release；API SearchType:web） - web_search 成功 doubao_search · 1,970 ms
豆包搜索结果（原始查询:Vanda VQW-765 pipeline importance analyst peak sales social anxiety 2026；API SearchType:web） - web_search 成功 doubao_search · 1,172 ms
豆包搜索结果（原始查询:Vanda Pharmaceuticals stock reaction Phase 3 failure biotech pipeline miss next steps VQW-765 continue development；API SearchType:web）
原文全文
展开原文 · 2,717 字
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday shared an update regarding its clinical development pipeline.
The company’s Phase 3 trial evaluating VQW-765, a small molecule alpha-7 nicotinic acetylcholine receptor partial agonist, failed to achieve its primary objective.
The trial tested the drug as an on-demand therapy for adults suffering from acute social anxiety, but results showed no significant benefit over a placebo.
Trial Design and Participant Details
Study 3201 randomly assigned 546 adult participants, ranging in age from 18 to 65.
Each participant had a current diagnosis of social anxiety disorder and exhibited elevated baseline anxiety scores on both the Liebowitz Social Anxiety Scale and the Public Speaking Anxiety Scale.
Medical staff administered a single oral dose of either VQW-765 or a placebo in an equal ratio.
Following the dosage, researchers challenged the participants with the standardized Trier Social Stress Test.
The specific evaluation induces acute stress by requiring subjects to first prepare and subsequently deliver an interview-style speech to a panel of judges who provide zero feedback or encouragement.
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
Primary and Secondary Endpoints Missed
The trial’s primary endpoint focused entirely on the female participant population. Researchers measured the level of distress during the performance segment of the stress test using the Subjective Units of Distress Scale.
This scale requires participants to rate their personal nervousness from zero to 100. The data revealed that female subjects who consumed VQW-765 failed to demonstrate a statistically significant difference compared to the placebo group.
Additionally, the study missed its essential secondary endpoint. The drug did not sufficiently reduce subjective distress scores during the performance phase across the complete trial population involving both men and women.
Phase 2 Findings Unconfirmed
Vanda explicitly designed Study 3201 to verify the promising data generated during an earlier Phase 2 trial.
During that preceding study, subjects suffering from a history of performance anxiety reported numerically lower stress measurements after taking VQW-765 instead of a placebo.
Ultimately, the broader Phase 3 data could not replicate or confirm those initial findings.
VNDA Price Action: Vanda Pharmaceuticals shares were down 2.51% at $4.11 during premarket trading on Thursday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
The company’s Phase 3 trial evaluating VQW-765, a small molecule alpha-7 nicotinic acetylcholine receptor partial agonist, failed to achieve its primary objective.
The trial tested the drug as an on-demand therapy for adults suffering from acute social anxiety, but results showed no significant benefit over a placebo.
Trial Design and Participant Details
Study 3201 randomly assigned 546 adult participants, ranging in age from 18 to 65.
Each participant had a current diagnosis of social anxiety disorder and exhibited elevated baseline anxiety scores on both the Liebowitz Social Anxiety Scale and the Public Speaking Anxiety Scale.
Medical staff administered a single oral dose of either VQW-765 or a placebo in an equal ratio.
Following the dosage, researchers challenged the participants with the standardized Trier Social Stress Test.
The specific evaluation induces acute stress by requiring subjects to first prepare and subsequently deliver an interview-style speech to a panel of judges who provide zero feedback or encouragement.
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
Primary and Secondary Endpoints Missed
The trial’s primary endpoint focused entirely on the female participant population. Researchers measured the level of distress during the performance segment of the stress test using the Subjective Units of Distress Scale.
This scale requires participants to rate their personal nervousness from zero to 100. The data revealed that female subjects who consumed VQW-765 failed to demonstrate a statistically significant difference compared to the placebo group.
Additionally, the study missed its essential secondary endpoint. The drug did not sufficiently reduce subjective distress scores during the performance phase across the complete trial population involving both men and women.
Phase 2 Findings Unconfirmed
Vanda explicitly designed Study 3201 to verify the promising data generated during an earlier Phase 2 trial.
During that preceding study, subjects suffering from a history of performance anxiety reported numerically lower stress measurements after taking VQW-765 instead of a placebo.
Ultimately, the broader Phase 3 data could not replicate or confirm those initial findings.
VNDA Price Action: Vanda Pharmaceuticals shares were down 2.51% at $4.11 during premarket trading on Thursday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
66b25b5b84· 2026-10-15 20:55 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前